Kineta, Inc.

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • ADMET
      • Molecular Diversity
        • Natural Products
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines

Other Names/Subsidiaries

  • Kineta Chronic Pain
  • Kineta Immuno-oncology
  • Kineta RLB
  • KPI Therapeutics
  • Kv1.3 Therapeutics
  • Yumanity Therapeutics
See more in Biomedtracker

Latest on Kineta, Inc.

Scrip

Kineta Resumes Enrollment Of Anti-VISTA Antibody Trial

 
• By Joseph Haas

Kineta, Inc. and potential partner TuHura Biosciences revealed on 19 August that enrollment is resuming in the Phase I portion of a Phase I/II study of the anti-VISTA antibody KVA12123 in advanced

Scrip

Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sionna Gets CF Compounds AbbVie License

Scrip

Finance Watch: Kronos Reveals Second Round Of Job Cuts In Five Months

 
• By Mandy Jackson

Kronos Bio, Inc. implemented a restructuring plan in November that resulted in a 19% workforce reduction but extended its cash runway into 2026 and the company unveiled further cost cuts on 7 March t

Scrip

Yumanity To Reverse Merge With Kineta Two Years After Its Own Public Debut

 
• By Joseph Haas

Less than two years after going public via a reverse merger with troubled cystic fibrosis company Proteostasis Therapeutics, Inc. , Yumanity Therapeutics, Inc. is winding up its operations by selli